SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
Stefan Schreiber 1
Severine Vermeire 2
David T. Rubin 3
Silvio Danese 4, 5
Rajiv Mehta 6
Xavier Roblin 7
Paul Kwon 8
Paul van Hoek 9
Tomasz Masior 10
Rahul Barron 10
Franck-Olivier Le Brun 10
Mamoru Watanabe 11
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 UZ Leuven, Leuven, Belgium
3 University of Chicago Medicine, Chicago, United States
4 IRCCS Hospital San Raffaele, Milan, Italy
5 Vita-Salute San Raffaele University, Milan, Italy
6 Surat Institute of Digestive Sciences Hospital, Surat, India
7 University Hospital of Saint-Étienne, Saint-Étienne, France
8 Gilead Sciences Inc., Foster City, United States
9 Galapagos NV, Mechelen, Belgium
10 Galapagos GmbH, Basel, Switzerland
11 Tokyo Medical and Dental University, Tokyo, Japan
Topic
IBD
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]